expression, clustering/pathway analyses, immunostaining of skin biopsy specimens, and clinical trait correlations were performed. Results: Skin tape expression profiles were distinct from skin biopsy profiles and better sampled epidermal differentiation complex genes. Skin tape expression of 29 immune and epidermis-related genes (false discovery rate < 5%) separated patients with AD from healthy subjects. Agnostic gene set analyses and clustering revealed 50% of patients with AD exhibited a type 2 inflammatory signature (type 2-high endotype) characterized by differential expression of 656 genes, including overexpression of IL13, IL4R, CCL22, CCR4 (log 2 fold change 5 5.5, 2.0, 4.0, and 4.1, respectively) and at a pathway level by T H 2/dendritic cell activation. Both expression and immunostaining of skin biopsy specimens indicated this type 2-high group was enriched for inflammatory, type 2-skewed dendritic cells expressing FcεRI. The type 2-high endotype group exhibited more severe disease by using both the Eczema Area and Severity Index score and body surface area covered by lesions. Conclusion: Minimally invasive expression profiling of nonlesional skin reveals stratification in AD molecular pathology by type 2 inflammation that correlates with disease severity. (J Allergy Clin Immunol 2018;141:1298-309.)
Key words: Skin, atopic dermatitis, RNA sequencing, type 2 immune response, inflammation Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the general population, with a prevalence of up to 25% in children and up to 7% in adults.
1,2 A large proportion of patients experience sleep disturbance and impaired quality of life. AD is caused by the complex interplay between epithelial and immune-driven abnormalities. 3, 4 The role of genetics in epithelial dysfunction is demonstrated clearly by the robust association of AD development and filaggrin (FLG)-null mutations, which disrupt healthy skin barrier function. [5] [6] [7] Similarly, the contributions of immune dysfunction to AD have been substantiated by strong associations of disease status with genetic variants in the signal transducer and activator of transcription 3 (STAT3), IL13, thymic stromal lymphopoietin (TSLP), and IL-1 receptorlike 1 (IL1RL1) genes, as well as the human leukocyte antigen (HLA) gene locus. 8, 9 Moreover, the involvement of both immune and epithelial constituents in AD pathology is corroborated by the efficacy of both skin emollients and T-cell therapeutics, such as cyclosporine. 10, 11 These genetic studies are also revealing because of the small increase in disease risk estimated to be conferred by any one of these loci. 8 This is in contrast to the high heritability of AD estimated from twin studies. 12 Although there are many potential explanations for these observations, the existence of multiple AD subgroups stratified by pathobiological mechanisms, or endotypes, might explain this phenomenon. 13 Further supporting this endotypic model of AD are recent drug trials of dupilumab, an IL-4 receptor (IL-4R) antagonist, which produced clearing or near clearing of AD skin disease in approximately 40% of patients. 14, 15 An inability to easily stratify patients by individual disease profile confounds tests of significance in both genetics and clinical trial studies. Moreover, approval of dupilumab and similar drugs creates an urgent need to identify endotypespecific treatment response groups. The precision medicine that AD endotyping would allow could have significant benefits to individual patients and the health care system in reducing expense, treatment failures, and risk of significant side effects. Gene expression profiling of RNA isolated from skin biopsy specimens has revealed significant differences in expression profiles of patients with AD, implicating type 2 immune pathways, as well as dysregulation of the skin barrier, through modification of cornification genes and lipid biosythesis. [16] [17] [18] [19] However, the requirement for large, scar-producing biopsies of lesional skin to obtain RNA amounts sufficient for expression profiling has impeded the study of AD disease endotypes in both clinical and research settings. Here we describe a minimally invasive method for sampling and gene expression profiling of nonlesional and lesional skin from patients with AD. We used these gene expression profiles to reveal molecular dysfunction of the skin and to stratify AD patients by their molecular disease endotype. ], 34% 6 4%). Study subjects with AD had not received topical corticosteroids, topical calcineurin inhibitors, or topical or oral antibiotics for 1 week before enrollment. Patients were not treated with systemic immunosuppressive medications for more than 1 month before enrollment in this study. The study was approved by the Institutional Review Board at National Jewish Health, Denver, Colorado. With more than 25 years of conducting clinical research studies (both industry and investigator initiated) on AD at National Jewish Health, we have a large database of research participants from which we prescreen and select depending on the inclusion/ exclusion criteria of the protocol. We estimate that 80% of those approached from that database and prescreened ended up qualifying for the protocol and then enrolling. Common reasons for exclusion included eczema that was not active or a disallowed medication, such as antibiotics, oral steroids, or both. All subjects provided written informed consent before participation in the study.
METHODS

Subject recruitment
Skin tape strip sampling was done for all study participants. In addition, 2 optional 2-mm skin punch biopsy specimens were collected from the nonlesional skin area of the upper extremities. One of the biopsy specimens was dissociated into the epidermis and dermis after 1 hour of digestion at 378C in 5 U/mL dispase diluted in PBS (catalog no. 354235; Corning, Corning, NY). Isolated epidermal and dermal samples were immediately submerged in RLT buffer (Qiagen, Valencia, Calif) and frozen at 2808C for future RNA isolation. The second biopsy specimen was preserved in 10% buffered formalin for immunofluorescent staining.
Tape strip collection and RNA extraction
A total of 20 consecutive D-Squame tape strips (22 mm in diameter; CuDerm, Dallas, Tex) were collected from the volar surface of the forearm. Previous skin biopsy studies of tape-stripped sites had shown that the depth of tape stripping included the upper half of the stratum granulosum, which includes viable cells containing RNA (Kim, Goleva, and Leung, unpublished data). Both nonlesional and lesional skin from patients with AD and skin from healthy control subjects was sampled. On application of the first tape disc, 4 marks were placed around the disc with a pen so that subsequent discs could be applied to the same location. Each tape disc was placed adhesive side up in a separate well of the two 12-well plates allocated for sample collection. Plates were kept on dry ice during tape strip collection. Collected tape strips 11 through 20 were sequentially scraped into the RLT buffer (Qiagen) and frozen at 2808C. RNeasy Micro Kits (Qiagen) were used according to the manufacturer's protocol to isolate RNA from skin tape strips, epidermis, and dermis.
Immunohistochemistry
Paraffin-embedded skin tissue samples were cut at 5 mm on frosted microscope slides. By using toluene and a series of ethanol washes, slides were deparaffinized and then rehydrated. Skin sections were then blocked with 5% BSA in Super Block (ScyTek Laboratories, Logan, Utah) containing 10% nonimmune donkey serum (Jackson Laboratories, West Grove, Pa) for 60 minutes. Slides were stained with rabbit anti-langerin (ab192027; Abcam, Cambridge, Mass) or rabbit anti-IL-4R (ab131058; Abcam) antibodies or control rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, Calif) at 48C overnight. Slides were washed with PBS/Tween 0.05%, followed by incubation with Cy3-conjugated donkey anti-rabbit IgG (Jackson Laboratories, West Grove, Pa). Nuclei were visualized with 49-6-diamidino-2-phenylindole dihydrochloride, and wheat germ agglutinin-conjugated fluorescein isothiocyanate was used to stain the cytoskeleton.
Immunofluorescent staining was visualized with a fluorescence microscope (Leica, Wetzlar, Germany). All skin samples were evaluated by a blinded observer. Slides were evaluated under 325 and 340 magnification oil immersion objectives. For IL-4R staining, mean fluorescence intensity was determined for the epidermal area. For langerin staining, the number of langerin-positive dendrites per 170 mm of the granular layer of the epidermis was counted. Slidebook 6.0 software (Intelligent Imaging innovations, Denver, Colo) was used for image acquisition and analysis.
RNA transcriptome gene expression and quality control RNA AmpliSeq libraries were constructed and barcoded with the Ion AmpliSeq Transcriptome Human Gene Expression Kit and methods. For skin tape RNA, because yields were less than the 10 ng used as standard input for AmpliSeq, we instead loaded the maximum volume of RNA (from a 12-mL extraction), the reaction could accommodate for all samples (3.5 mL). Average inputs for skin tape samples were 0.11 6 0.17 ng. Yields were higher for skin biopsy epidermal and dermal samples but less than the 10 ng needed for standard input in most cases. Average inputs for epidermal and dermal samples were 3.55 6 3.24 and 1.69 6 2.52 ng, respectively. Barcoded RNA sequencing (RNA-seq) libraries were pooled and sequenced on the Ion Torrent Proton sequencer by using P1 chips.
Sequencing reads were mapped to AmpliSeq transcriptome target regions with the torrent mapping alignment program and quantified with the Ion Torrent AmpliSeq RNA plugin using the uniquely mapping option. Duplicated sequences were removed from the FASTA file, and incorrect amplicon locations were corrected, as previously reported. 20 Samples with total read counts of greater than 8 3 10
6 were downsampled to 8 3 10 6 reads. The average total read counts for skin tape, epidermal, and dermal samples were 7.84 3 10 6 6 5. Normalization and differential expression analysis of RNA-seq data Gene counts were normalized and differential expression was performed with the DESeq2 R package, 21 which is distributed by Bioconductor.
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DESeq2 was used to perform multiple testing correction by applying the Benjamini-Hochberg procedure at a false discovery rate (FDR) of 0.05.
Gene set enrichment
The Enrichr 23 Web tool was used to test for enrichment of gene ontology (GO) categories in the 500 most highly expressed genes from each sampling technique. Generally Applicable Gene Set Enrichment (GAGE) 24 was used to perform functional enrichment analyses of GO categories. Gene Set Enrichment Analysis (GSEA) software 25 was used to perform leading-edge analysis of the significantly enriched GOs and identify the genes driving enrichment of each ontology category. Qiagen's Ingenuity Pathway Analysis (www.qiagen. com/ingenuity) was used to perform Canonical Pathway Analysis of the type 2-high versus type 2-low differential expression results.
Statistical methods and plot generation
All statistical analyses outside bioinformatics programs were performed in R statistical language. Hierarchical clustering was performed with the hclust function of the stats package. Heat maps were generated with the heatmap3 package. Principal component analysis was performed with the prcomp function of the stats package. All other plots were generated by using the ggplot2 package in concert with the reshape, ggrepel, lattice, grid, and gridExtra packages.
Dendritic cell comparisons
Microarray data sets of dendritic cell (DC) subsets were downloaded from the National Center for Biotechnology Information Gene Expression Omnibus 26 by using the Geoquery R package, 27 which is distributed by Bioconductor. 22 Expression of monocyte-derived DCs and Langerhans cells (LCs) was obtained from the work of Szeles et al (available at accession no. GSE23618). 28 Expression of plasmacytoid dendritic cells (pDCs) and LCs was obtained from the work of Hutter et al (available at accession no GSE35340). 29 Differential expression of these cell types was performed with the limma R package, 29 which is distributed by Bioconductor 22 and implements a moderated t test, and the resulting P values were adjusted by using the Benjamini-Hochberg multiple-testing procedure. Genes were considered differentially expressed, with an FDR of 0.05 or less.
RESULTS
The skin tape transcriptome identifies a unique epidermal molecular profile in nonlesional AD skin
We collected nonlesional skin tape samples from 30 patients with AD and 25 healthy control subjects. RNA extraction resulted in average total RNA yields of 260.33 pg (SD, 411.70 pg). Although these RNA amounts were too low for standard RNAseq, we proceeded to generate AmpliSeq whole-transcriptome sequencing libraries for all samples. This method is based on the multiplexed amplification of cDNA amplicons for more than 20,000 genes in a single reaction. 20, 30 The cDNA amplicons were converted into an Ion Torrent sequencing library, with sequencing used to generate digital count data. This method has been used previously to robustly generate libraries in settings in which RNA quantity and quality are limited. Sequencing data were successfully generated from nonlesional skin for 18 (60%) patients with AD and 13 (52%) healthy control subjects (P 5 .35). We found an average of 14,520 and 13,201 genes expressed in patients with AD and healthy control subjects, respectively. Among the top 10 expressed genes (Fig 1, A) were FLG, FLG2, small proline-rich protein 2E (SPRR2E), and keratin 10 (KRT10), all of which are known to be highly expressed in the keratinized epidermal epithelium.
To compare the molecular information contained in the skin tape transcriptome with skin biopsy specimens, we generated transcriptomes from the epidermis and dermis of separated nonlesional skin biopsy specimens collected from skin-taped subjects concurrent with skin taping at adjacent sites. Sample clustering was performed by using multidimensional scaling of the most variant genes across all 3 data sets. Samples were separated based on epidermal, dermal, and skin tape sample types (Fig 1, B) . GO analysis of the most highly expressed genes among each sample type supported a greater similarity between the molecular profiles of skin tape and epidermal than skin tape and dermal samples (Fig 1, C) . Specifically, the cornified envelope, desmosome, and intermediate filament GO categories, which are characteristic of the granular layers of the keratinizing epidermis, were among the top 10 GO enrichments for only the epidermis and skin tape.
Because tape strip sampling collects the most superficial layers of the skin, we hypothesized that late cornification genes would be most highly expressed in the skin tape samples. Comparing expression of these late cornification envelope genes between the sample types, we found the lowest expression of these genes in dermal samples, high expression of these genes in the epidermal samples, and the highest expression in skin tape samples (Fig 1, D) .
Nonlesional skin tape gene expression reflects AD disease status
We then performed single-gene differential expression between nonlesional AD (n 5 18) and healthy control (n 5 13) skin tape transcriptomes. We identified 29 differentially expressed genes (FDR < 0.05), all of which were upregulated in patients with AD. Hierarchical clustering of expression for these genes separated patients with AD from healthy subjects (Fig 2, A) . Among the upregulated genes in patients with AD was the cysteine leukotriene receptor 1 (CYSLTR1), a major mediator of hypersensitivity and allergy, which is expressed on mast cells, basophils, and eosinophils. 31 We also identified small proline-rich protein 2F (SPRR2F), a gene that encodes a protein involved in cell membrane cross-linkage in keratinocytes, 32 and might have a role in antimicrobial responses. Also among these genes were 2 matrix metalloproteinase (MMP) genes: MMP9 and MMP10. Another of these upregulated genes, coiled-coil domain containing 80 (CCDC80), has been identified in a recent AD genome-wide association analysis. 33 The top differentially expressed gene determined by using FDR, HLA-DOB, encodes the b chain of the HLA class II major histocompatibility DO complex. The HLA-DO complex is involved in inhibition of antigen loading and presentation by HLA-DM. 34 Gene set analysis reveals a subgroup of AD patients with a strong immune activation signature in their nonlesional skin To identify functional groupings or pathways of genes altered in nonlesional skin tape samples from patients with AD, we used the GAGE package to perform gene set enrichment analysis of predefined GO categories. In patients with AD versus healthy control subjects, we identified 154 and 11 GO terms that were upregulated and downregulated, respectively (see Table E1 ). To eliminate redundancy in this analysis, we identified the genes contributing most to these gene set associations by performing GSEA on the significant GO categories. This resulted in 1455 significant leading-edge genes across all GO categories (see Table E2 in this article's Online Repository at www. jacionline.org). We performed hierarchical clustering of all subjects based on the 75 most frequently enriched of the leading edge genes (Fig 2, B) . Interestingly, we found upregulation in these genes was driven by a subset (9/20) of patients with AD and that the remainder of patients with AD had low expression of these genes similar to that seen in healthy control subjects (Fig 2, B) . We defined this group of patients with AD as patients with evidence of immune cell activation.
The type 2-high AD endotype is defined by antigenpresenting cell and T-cell signaling and activation signatures in nonlesional AD skin
To determine the molecular nature of AD in immune-activated subjects, we performed differential expression analysis of nonlesional skin RNA transcripts between this group (n 5 9) and patients with AD not exhibiting this immune activation signature (n 5 9). We identified 656 differentiated expressed genes between these 2 groups of patients with AD, including 599 and 57 upregulated and downregulated genes, respectively (see Table E3 in this article's Online Repository at www.jacionline.org). We performed canonical pathway analysis of the dataset with Ingenuity Pathway Analysis and observed the T H 2 cell pathway was most significantly enriched (5.0 3 10
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; Fig 3, A) . Supporting this, the canonical type 2 cytokine IL13 was highly upregulated in these subjects (log 2 fold change [FC] 5 5.5; Fig 3, B) . Moreover, other welldescribed type 2 pathway genes were upregulated, including C-C motif chemokine receptor type 4 (CCR4) (log 2 FC 5 4.1), IL4R (log 2 FC 5 2.0), and C-C motif chemokine 22 (CCL22) (log 2 RARA  BCL10  IRF1  PTPN6  IL4R  SRC  LYN  HLA−DMA  CD4  FCER1G  IRF4  XBP1  CD83  CD40  STAT5A  ZP3  TNFSF9  CD59  IL23A  IFNB1  FOXJ1  TNFSF4  VTCN1  HLA−G  BTK  CD300A  ADA  IL7  TLR4  LILRB2  EBI3  TNFSF11  CARD11  IL12B  KLRK1  IL10  IL13  BTLA  IL12RB1  PRKCQ  PRKCA  CCL2  P2RX7  CCL21  CCL19  TGFBR2  NOD2  JAK3  CD3E  HLX  CCL5  CD28  IL1B  AIF1  TNF  ADAM8  HLA−DQA2  CCL3  CD274  NCKAP1L  CD86  TNFSF13B  CD80  SASH3  PIK3CG  IL2RA  FOXP3  CCR7 FC 5 4.0; Fig 3, B) . Based on this expression pattern, we labeled the immune-activated subjects as type 2-high subjects and the nonactivated subjects as type 2-low subjects. Examining the top 15 most significant canonical pathways in type 2-high samples, we found many centered on the activation of and signaling between T H cells and antigen-presenting cells (APCs ; Fig 3, C) . For example, 6 APC MHC class II receptor genes (HLA-DOB, HLA-DOA, HLA-DMA, HLA-DPA1, HLA-DPB1, HLA-DRA, and HLA-DRB1) were upregulated in the type 2-high group, as were the APC costimulatory receptors (cluster of differentiation genes) CD80, CD86, and CD40. In line with APC-driven activation of T H cells, we found upregulation of CD28, CD3, inducible costimulator, IL-2 receptor, and IL-25 receptor.
Our IL4R result was confirmed at the protein level in granular epidermal layers by using immunohistochemistry: we found significantly higher IL-4R staining based on mean fluorescence intensity in patients with type 2-high AD versus either healthy control subjects or patients with type 2-low AD (Fig 4) . In total, these results are supportive of active enhanced APC-T-cell signaling in the superficial skin layers of patients with type 2-high AD.
The nonlesional skin of patients with type 2-high AD is characterized by upregulation of inflammatory DCs
Given the strong APC signal among the patients with type 2-high AD and that DCs are a common APC population in the skin, we investigated whether these APC signals reflected specific DC gene expression patterns. Specifically, we considered resident epidermal dendritic LCs but also 2 populations of peripherally derived DCs that have been described to infiltrate AD skin: Immune activation signature in patients with AD reflects significant upregulation of type 2 inflammatory genes and the presence of activated T H 2 and DCs. A, Ingenuity Pathway Analysis canonical pathway analysis was performed with nonlesional skin tape differentially expressed genes between immune-activated patients with AD and nonactivated patients with AD. The 15 most significantly enriched canonical pathways indicate upregulation of T H 2 and DC activity in immune-activated patients with AD. iCOS, Inducible costimulator; iCOSL, inducible costimulator ligand; NFAT, nuclear factor of activated T cells; PKC, protein kinase C. B, Expression of canonical type 2 inflammatory genes is upregulated in skin tape samples of immune-activated patients with AD. C, Graphic display of the canonical Ingenuity Pathway Analysis T H 2 pathway showing genes overlaid on an APC and a T cell. Differentially expressed genes are colored by log 2 FC. TCR, T-cell receptor.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 4 inflammatory dendritic epidermal cells (IDECs) and plasmacytoid dendritic cells. We found upregulated expression for multiple markers of all 3 DC subsets in our subjects with type 2-high AD versus those with type 2-low AD (Fig 5, A) .
28,29
To better refine the potential DC subset source of these markers, we generated relative expression plots between LCs and both IDECs and pDCs using previously reported DC expression profiling data (Fig 5, A) . 28, 29 The more general markers of DCs, CD1A, CD1B, and CD1C, were all upregulated in patients with type 2-high AD. The CD83 gene, which we find to be highly enriched in LCs, was also upregulated in patients with type 2-high AD. Moreover, examining expression of CD207, the gene that encodes the langerin protein and marker of LCs, we found significant upregulation in patients with type 2-high AD (FC 5 2.2, FDR 5 0.018; Fig 5, A) . Supporting this, immunohistochemistry of the granular epidermal layers revealed progressively higher numbers of langerin-positive dendrites in healthy control subjects, patients with type 2-low AD, and patients with type 2-high AD (Fig 5, B and C) . The FCER1A (enriched in LCs) and FCER1G (enriched in IDECs) genes combine to produce the trimeric (ag2) form of FcεRI, which has been observed in LCs and IDECs in skin of patients with lesional AD. Moreover, these IgE Fc receptor genes have been shown previously to be upregulated by type 2 cytokines, including IL-13. In contrast, the b subunit (MS4A2), which combines with the a and g subunits to produce the tetrameric form (agb2) of the FcεRI receptor and is expressed by mast cells and basophils, 35 was not expressed in our subjects. In general, we found the genes upregulated in patients with type 2-high AD were skewed toward higher expression in IDECs versus LCs (Fig 5, D) . 28, 29 In fact, CD209 (DC-specific intercellular adhesion molecule 3-grabbing nonintegrin), CD11C (integrin subunit alpha X), and CD11B (integrin subunit alpha M), markers that strongly differentiate IDECs from LCs, were strongly upregulated in patients with type 2-high AD. Finally, we also observed that the IL3RA gene (CD123), a marker of pDCs, was the most strongly upregulated gene in patients with type 2-high AD. Together, these data support strong upregulation of resident and infiltrating inflammatory DC sets in the nonlesional skin of patients with type 2-high AD.
AD clinical severity measures are strongly related to the nonlesional skin type 2-high gene signature Examining the severity classification of patients with AD based on IGA scores, we observed 4 of 9 type 2-high subjects had severe disease (IGA score 5 4) versus only 1 of the 11 patients with type 2-low AD. Therefore we explored the relationship between expression of the type 2-high signature genes and several clinical measures of AD severity. To accomplish this, we performed principle component analysis of the 656 genes associated with type 2-high status. The principal components (PCs) generated were tested for correlation with EASI severity scores for all patients with AD. We found PC2 exhibited a strong correlation (r 5 0.616, P 5 9.79 3 10 23 ) with EASI scores (Fig 6, A) . Relatedly, PC2 was also strongly correlated with BSA covered with lesions (r 5 0.438, P 5 1.45 3 10 22 ; Fig 6, B) . PC2 values also exhibited a striking correlation with IgE levels (r 5 0.705, P 5 6.96 3 10 25 ), reflecting the highly allergic nature of these subjects and this gene set (Fig 6, C) . We also noted increased correlation of serum IgE levels and BSA with PC2 when only the type 2-high subjects were analyzed (r 5 0.811 and .643, respectively). Supporting these quantitative relationships, PC2 values were strongly associated with severity status, with a median value of 26.94 for mild (IGA score 5 2), 22.00 for moderate (IGA score 5 3), and 5.19 for severe (IGA score 5 4) disease (P 5 5.12 3 10 22 ; Fig 6, D) . Considering the strong relationship between the nonlesional type 2-high expression signature and AD severity, we hypothesized the lesional skin expression profile would be similarly upregulated in the nonlesional skin of patients with type 2-high but not type 2-low AD. Therefore we generated lesional skin tape transcriptomes on 12 subjects. We clustered the nonlesional and lesional skin samples on the top 250 genes differentially expressed in lesional skin versus healthy control skin (see Table E4 in this article's Online Repository at www.jacionline.org). We found nonlesional skin from patients with type 2-high AD clustered with lesional skin samples, whereas healthy control and nonlesional type 2-low skin clustered separately (Fig 6, E) . (Fig 4, A) and type 2-low (Fig 4, B) AD. IL-4R (Cy3) is shown in red, wheat germ agglutinin (fluorescein isothiocyanate) is shown in green, magnification is 3400, and the bar equals 20 mm. Arrows point to IL-4R-expressing keratinocytes in the epidermis. C, Quantification of IL-4R staining revealed significantly greater IL-4R levels in nonlesional skin of patients with type 2-high than patients with type 2-low AD.
DISCUSSION
Over a decade of genomic profiling studies examining skin punch biopsy samples from patients with AD has revealed significant heterogeneity in disease mechanisms. Various studies have implicated permutations of excessive T H 2, T H 22, and, to a lesser extent, T H 17 activation and inflammation in AD skin. 17, 36, 37 Some of these and other studies have also implicated deficiencies in either or both lipid synthesis and terminal skin differentiation genes. 5, 17, 19, 38, 39 The heterogeneity in disease mechanisms across the population of patients with AD coupled to the development of targeted biological therapeutics has created an urgent need for methods that allow query of the AD skin transcriptome endotype. Recent studies in the Journal of Allergy and Clinical Immunology have highlighted the importance of epithelial abnormalities and immune activation in the pathogenesis of AD. 3, 4 Skin transcriptome measurements could allow stratification of patients to endotype groups for large research studies (eg, genetic), assignment to targeted biologic therapy, and facilitation of biological measures of treatment response with repeat sampling. Although skin punch biopsy genomic profiling has elucidated disease mechanisms well, its widespread adoption is impeded by the invasive and scarring nature of the sampling.
Our article details the use of a much less invasive and nonscarring method of tape stripping to collect skin from patients with AD. In line with the small tissue quantities collected by using this technique, the yield of RNA from the tape strips was significantly less than from skin punch biopsy specimens. Therefore we adopted a well-described 20, 30, 40 transcript amplicon enrichment method (AmpliSeq) to generate full transcriptomic sequencing data from subnanogram total RNA levels. This method is also robust to RNA degradation because only short transcript fragments of 100 to 200 bp are required. We have previously used this method successfully for endotyping of asthmatic patients by using RNA isolated from sputum and nasal airway Nonlesional skin of patients with type 2-high AD is characterized by inflammatory DC signatures. A, Gene expression log 2 FCs for DC markers between nonlesional skin of patients with type 2-high versus patients with type 2-low AD is plotted. Gene expression log 2 FCs for these DC genes in published IDECs or monocyte-derived DCs versus Langerhans DCs 28 and pDCs versus Langerhans DCs. 29 B, Immunohistochemistry of skin biopsy specimens reveals numbers of CD207 1 (langerin) DCs are greatest in patients with type 2-high AD, followed by patients with type 2-low AD and healthy control subjects. C, CD207 (langerin) staining of skin biopsy specimens from patients with type 2-high AD reveals extension of DC dendrites into the superficial layers of the epidermis. Langerin (Cy3) is shown in red, wheat germ agglutinin (fluorescein isothiocyanate) is shown in green, magnification if 3400, and bar equals 20 mm. Arrows point to langerin-positive cells and dendrites in the upper granular layer of the epidermis. Fluorescein isothiocyanate/Cy3 channels or the Cy3 channel only are shown. D, Genes upregulated in nonlesional skin of patients with type 2-high versus patients with type 2-low AD are plotted by using log 2 FCs of differential expressions from IDECs versus Langerhans DCs 28 and pDCs versus Langerhans DCs 29 generated from published gene expression data. Log 2 FCs of type 2-high upregulated genes indicate a skew toward IDECs. Plotted genes were filtered by using a significance threshold of an FDR of less than 0.05. J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 4 epithelial cells. 30 This sampling method not only collects less skin but also assays a more superficial epidermal layer.
This was made clear by the distinct clustering of skin tape samples by transcriptome in comparison with the separated epidermal and dermal biopsy layers. In line with the superficial nature of the sample, the skin tape transcriptome was most closely related to the epidermal samples but with even higher expression of late cornification genes, including FLG, FLG2, and LCE and SPRR family genes.
We observed a set of 29 significantly upregulated genes in AD tape strips that exhibited sufficient differences to separate patients with AD from healthy subjects by using hierarchical clustering. This included multiple genes previously observed to be upregulated in nonlesional AD skin, including MMP9, MMP10, and S100A7A, which is supportive of previous work linking MMP function and disruption of barrier function in patients with AD. 17, 19, 36, 41 One of the most consistently highly expressed genes across subjects was the receptor for cysteinyl leukotrienes (CYSLTR1). Expression of this gene is induced by type 2 cytokines and tightly linked with hypersensitivity in multiple diseases. 42, 43 Also of great interest was identification of the CCDC80 gene as upregulated in patients with AD. The CCDC80 gene is one of only 8 loci identified in an AD genome-wide association analysis of Japanese subjects. 33 The CCDC80 protein has been shown to function in control of energy homeostasis, with its deletion in mice resulting in obesity. 44 Additionally, CCDC80 is strongly upregulated in both mouse and rat models of pulmonary arterial hypertension, as well as among human pulmonary arterial hypertension disease. 45 Although it is unclear how CCDC80 might function in patients with AD, the independent genome-wide significant genetic and genomic signals for this gene suggest extensive study of CCDC80 in patients with AD is warranted. We did not observe widespread downregulation of terminal differentiation genes, as reported by Suarez- Farinas et al 17 in a nonlesional skin punch biopsy study. These differences might be a function of the less severe nature of our subjects, which included patients with mild disease. Additionally, we note the Cole et al 19 nonlesional AD skin study did not find this widespread terminal differentiation gene downregulation but instead detected increases in FLG expression in non-FLG mutation AD carriers versus control subjects. Finally, we suggest that the superficial epidermis sampled by tape strips provides a more like-to-like comparison of skin between healthy subjects and patients with AD than skin punch biopsies would allow because AD dramatically alters the epidermal and dermal layer thicknesses. These alterations in layer thickness could dramatically influence the expression levels observed when comparing whole biopsy specimens between AD and healthy skin.
Although multiple immune-related genes were among the 29 detected in the differential expression analysis, pathway analysis identified a much stronger pattern of immune activation and inflammation in patients with AD. Hierarchical clustering of subjects based on these immune activation pathways revealed the striking stratification in gene expression among patients with AD, explaining the lack of association in the single-gene analysis among the entire group. Examination of this immune-activated group of patients with AD found more than 600 differentially expressed genes. A strong upregulation of type 2 inflammatory signatures (high IL13, IL4R, and CCL22) differentiated the immune-activated subjects from other patients with AD who exhibited type 2 gene expression levels similar to those of healthy control subjects. This type 2-high group exhibited a strong signature of T H 2 cell activation, including upregulated inducible costimulator and CD28 signaling, replicating signals observed in both AD lesional and nonlesional skin from a recent AD transcriptome meta-analysis. 16 These findings are also in line with 2 prior immunohistochemistry studies that found increased numbers of T cells in the nonlesional skin of patients with AD versus healthy control skin. 18, 46 An equally prominent component of the patients with type 2-high AD was the activated DC signature. We observed increased expression of CD207 and other markers of resident Langerhans DCs. We confirmed an increased presence of these Langerhans DCs in the stratum corneum of patients with type 2-high AD versus healthy control subjects and the extension of the langerinpositive dendrites upward in the upper granular layer of the nonlesional skin of patients with type 2-high AD. Relatedly, recent work found activated LCs elongate their dendrites to penetrate keratinocyte tight junctions and survey the environment located outside of the tight junction barrier, likely capturing antigens, a process that was significantly enhanced in skin of patients with lesional AD. 47 Examination of the type 2-high AD gene signature for Langerhans DCs versus monocyte-derived inflammatory infiltrating DCs (IDECs) indicated the expression pattern among the patients with type 2-high AD was more enriched for the IDECs. Additionally, we found specific markers of pDCs, IL3RA and CLEC4C, were highly upregulated in patients with type 2-high AD, with IL3RA being the top upregulated gene in the type 2-high group. Finally, we found upregulated expression of FcεRI subunits, as expressed by DCs (FCER1A and FCER1G), in patients with type 2-high AD. We note that prior studies have found increased numbers of CD11C 1 DCs in nonlesional AD skin and that another study found increased FcεRI staining in nonlesional skin DCs for patients with AD. 48, 49 Taken together, our data are supportive of increased penetration into the skin stratum corneum of multiple highly activated DCs subsets among patients with type 2-high AD. Interestingly, we found the nonlesional type 2-high skin endotype was strongly related to disease severity, as judged by multiple measures, including EASI scores and percentage BSA covered by lesions, revealing the clinical value of this endotype. Our observations of heterogeneity in nonlesional skin type 2 inflammation and its relationship with clinical severity and lesional skin expression profile is in agreement with the skin biopsy transcriptome study by Suarez-Farinas et al. 17 This study found complete separation of lesional skin from the skin of healthy subjects based on transcriptome pattern, with nonlesional AD skin occupying a continuum from healthy to lesional AD skin. In this study inflammatory gene expression (mostly type 2) in nonlesional skin was also strongly correlated with SCORADmeasured disease severity. Likewise, our lesional data on skin tape strips indicate a much more uniform pattern of type 2 inflammation than the dichotomous nature of the nonlesional samples. Taken together, these results suggest that although most exacerbations of AD involve type 2 inflammation, the type 2 inflammatory state of the visibly unaffected skin associates with severity.
We noticed the parallel between our results and the type 2-high endotype observed in both the baseline bronchial and nasal airways of asthmatic subjects, in which disease severity also associates with type 2-high endotype. In fact, the observed frequency of the type 2-high airway endotype is approximately 50% across several studies. 30, 50 We speculate that the baseline type 2 inflammation observed in both the airways and skin might involve the same systemic immune system skew and drive development of the respective type 2-high endotypes of these diseases. This mechanism is consistent with the strong association between AD, asthma, and other allergic diseases.
The ease of our technique has potential for paired use in the development and eventual clinical administration of multiple biologics under development, most notably type 2 cytokine pathway inhibitors. Dupilumab, an IL-4Ra blocker, has now been shown to improve nearly all severity measures in 2 different phase 3 clinical trials for moderate-to-severe AD. 14, 15 Despite its success, only approximately 40% of subjects experienced success for the primary outcome (complete clearing or almost clear AD) in these trials. We speculate that these subjects could be identified a priori by using nonlesional skin tape transcriptome analysis. We note both gene expression and protein staining of IL-4Ra was increased in patients with type 2-high AD. The use of skin transcriptomics as a suitable biomarker for response is also supported by an earlier dupilumab study, which found transcriptomic profiles for lesional skin improved with treatment and correlated with clinical response. 51 We acknowledge several limitations to our current study. First, the transcriptome generation failed in approximately 40% of nonlesional AD skin samples because of a lack of RNA. We acknowledge the possibility that this failure rate could have skewed the relative percentages of subjects in the skin endotype groups. However, in comparing the severity measures and transcriptomes (see Fig E1 in this article' s Online Repository at www. jacionline.org) of the failed-to-successful samples, we do not see any relationship. This high failure rate could also impede deployment of nonlesional skin tape profiling in research and clinical practice. However, we are currently working to improve the sampling and extraction procedure. In fact, we resampled 11 of the subjects in whom a successful skin tape transcriptome was not generated on the first attempt reported in this article and were able to generate successful libraries on all subjects with repeat sampling. The nonscarring nature of the sample collection makes patients much more likely to provide a sample initially and repeatedly. In fact, in this study we find the consent rate for skin tape stripping was 100% in contrast to only 40% for skin biopsies, when biopsy sampling was suggested as optional.
Lastly, we note the success rate for lesional AD skin tape transcriptome analysis was 86%. This higher rate is likely due to the increased immune cell load in lesions, with resultant higherquality RNA. The lesional skin analysis could serve as an important tool to judge reduction in inflammatory and other immune characteristics in clinical trials for all subjects, as has been shown previously. Furthermore, the high failure rate in nonlesional AD skin might reflect a low level of immune activation and cell infiltration in a subset of subjects. We draw attention to the concept that barrier properties that differ between patients with AD and healthy control subjects or between patients with type 2-high and type 2-low AD could result in differential skin sampling depth. These depth differences could drive broad expression profile differences given the multilayered nature of the skin. This clearly is not the case for patients with AD versus healthy control subjects in our current study because only a limited number of genes were differentially expressed, and these genes were not relegated to only skin differentiation states or layers. Likewise, this does not appear to be the case for the type 2-high versus type 2-low AD comparison. Most genes differentially expressed here were immune (rather than skin layer) related. If anything, our skin tape results for AD and type 2-high differential expression show considerably less variation in skin layer and barrier-related genes than prior skin biopsy transcriptome studies, where the portion of the biopsy originating from different skin layers (epidermis vs dermis) might have indeed played a role in results.
An interesting aspect of the study is the immune signature readout in such superficial skin collected by tape stripping. However, as noted in our histology and others' results, infiltration of inflammatory immune cells into the superficial skin layers is a real phenomenon. Clearly, this is also seen in our lesional skin results, where it was more expected.
In summary, we believe our endotypes truly identify type 2 inflamed subjects. We recognize that the participation of this study was limited to adult white subjects and that the scope of this work might not translate to pediatric AD. Further study of children is needed and would be facilitated by our methods. Finally, we also acknowledge the cross-sectional, single-sampling nature of our data. Future studies will need to be conducted that perform repeat sampling, varying time and body location. These studies would allow determination of persistence for this endotype and its potential uniformity across body location.
In summary, we detail a novel method for molecular analysis of skin from patients with AD, which is nonscarring and minimally invasive. Our method indicates an endotypic subgroup of patients with AD exists with high immune activation, positively associated with severity, and dominated by type 2 inflammation. With modifications to improve robustness, our method might have clinical application in precision medicine and allow, for the first time, birth cohorts and longitudinal disease evolution studies, which repeatedly sample and genomically evaluate the skin. These studies will likely be required to truly reveal the mechanisms, which underlie both the development and clinical course of AD.
